To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch.
The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. It includes a brief description of each study, an assessment of the reporting of some methodological quality features and the main conclusions of the report written by the Centre for Evidence in Transplantation (CET). RCTs and systematic reviews are selected by the Centre for Evidence in Transplantation on the basis of quality or interest. Electronic publications ahead of print are listed as [record in progress].
The first issue of the Transplant Trial Watch was published in September 2009. It is now made available to thousands of transplant professionals worldwide each month.
Click on each trial for more detail of findings and quality.
March 2012
Kidney transplantation
Good Outcomes with Cyclosporine Very Low Exposure with Everolimus High Exposure in Renal Transplant Patients.
Bertoni E, Larti A, et al Journal of Nephrology, 24(5): 613-618, 2011.
Incidence of Cytomegalovirus UL97 and UL54 Amino Acid Substitutions Detected After 100 or 200 Days of Valganciclovir Prophylaxis.
Boivin G, Goyette N, et al. Journal of Clinical Virology 53(3):208-13, 2012.
Polymorphisms in CYP3A5, CYP3A4, and ABCB1 Are Not Associated with Cyclosporine Pharmacokinetics Nor With Cyclosporine Clinical End Points After Renal Transplantation.
Bouamar R, Hesselink DA, et al. Therapeutic Drug Monitoring, 33(2): 178-184, 2011.
The Role of Proton Pump Inhibitors on Early Mycophenolic Acid Exposure in Kidney Transplantation: Evidence from the CLEAR Study.
Kiberd BA, Wrobel M, et al. Therapeutic Drug Monitoring, 33(1): 120-123, 2011.
Oseltamivir, an Influenza Neuraminidase Inhibitor Drug, Does Not Affect the Steady-state Pharmacokinetic Characteristics of Cyclosporine, Mycophenolate, or Tacrolimus in Adult Renal Transplant Patients.
Lam H, Jeffery J, et al. Therapeutic Drug Monitoring, 33(6): 699-704, 2011.
Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients: A Randomized Phase II Study.
Rostaing L, Massari P, et al. Clinical Journal of the American Society of Nephrology, 6(2): 430-439, 2011.
Improvement of Urinary Dysfunction After Kidney Transplantation by Administration of the Antimuscarinic Agent-Prospective Randomized Controlled Study.
Tsunoyama K, Ishida H, et al. Transplantation 93(6):597-602, 2012.
How Delayed Graft Function Impacts Exposure to Mycophenolic Acid in Patients After Renal Transplantation.
van Gelder T, Silva HT, et al. Therapeutic Drug Monitoring, 33(2): 155-164, 2011.
Liver transplantation
Sirolimus Conversion Regimen Versus Continued Calcineurin Inhibitors in Liver Allograft Recipients: A Randomized Trial.
Abdelmalek MF, Humar A, et al. American Journal of Transplantation 12(3):694-705, 2012.
Other
Randomized Study of Surgical Prophylaxis in Immunocompromised Hosts.
Lopes DR, Peres MP, et al. Journal of Dental Research, 90(2): 225-9, 2011.